Spirulina and schizophrenia: oxidative stress, neuroinflammation, and antipsychotic context

Schizophrenia neurobiology

Dopamine dysregulation:Excess dopaminergic activity in mesolimbic pathways (positive symptoms: hallucinations, delusions) and deficit in mesocortical pathways (negative symptoms: flat affect, avolition, cognitive impairment). All antipsychotics work primarily by D2/D3 receptor antagonism.
Glutamate excitotoxicity:NMDA receptor hypofunction in PFC interneurons disinhibits cortical glutamate release, contributing to cognitive symptoms and psychosis. This is the basis for the glutamate hypothesis of schizophrenia.
Oxidative stress:Reduced GSH (glutathione), elevated MDA (lipid peroxidation), reduced SOD activity, and elevated 8-OHdG (DNA oxidation) are consistently documented across schizophrenia cohorts. These findings predate antipsychotic treatment — they are part of the illness biology, not medication effects.
Neuroinflammation:PET imaging and post-mortem studies show elevated microglial activation in dorsolateral prefrontal cortex and temporal lobe in schizophrenia. Elevated IL-6, IL-8, and TNF-α in CSF. C-reactive protein is elevated in ~30% of patients.

Many antipsychotics cause significant metabolic side effects — particularly clozapine and olanzapine:

Weight gain (sometimes dramatic: 5–20 kg in the first year) via histamine H1, muscarinic M3, and serotonin 5-HT2C receptor blockade
Insulin resistance and type 2 diabetes risk; dyslipidaemia
Spirulina’s adiponectin-increasing and insulin-sensitising effects are practically relevant in this context — the cardiometabolic benefits of spirulina are most applicable here

Iron deficiency is disproportionately prevalent in schizophrenia:

Dietary restriction (negative symptoms reducing food preparation and intake), poverty and food insecurity in severe mental illness, and medication side effects affecting GI absorption all contribute
Iron is required for dopamine synthesis (tyrosine hydroxylase cofactor) and myelination — iron deficiency may worsen the dopaminergic deficits in prefrontal pathways contributing to negative symptoms
Spirulina’s iron provision is practically relevant in this population

Clozapine has special metabolic and haematological monitoring requirements (white cell count monitoring for agranulocytosis). NK stimulation from spirulina in clozapine-treated patients — who are already immunologically monitored — should be discussed with the clozapine clinic managing the patient.
Clozapine-associated constipation (common and sometimes severe) may be partially addressed by spirulina polysaccharides supporting butyrate producers.

NOX2 inhibition reduces superoxide in prefrontal microglia — addressing the neuroinflammatory component and the oxidative stress consistently documented in schizophrenia
Antioxidant provision (phycocyanin direct radical scavenging) may help restore the reduced glutathione and elevated lipid peroxidation markers
No clinical trial of spirulina or phycocyanin in schizophrenia exists. The mechanistic case is clear; clinical evidence is absent.

Always discuss with psychiatrist and care coordinator before introducing spirulina — schizophrenia management involves complex multi-professional coordination
The most evidence-based rationale is metabolic support (adiponectin, insulin sensitivity, lipid modulation) for antipsychotic-induced metabolic syndrome
Iron correction if ferritin <50 µg/L may support dopamine synthesis pathways and energy
3–5 g/day is appropriate starting dose; increase gradually
No known interaction with haloperidol, risperidone, quetiapine, or aripiprazole at spirulina doses; clozapine requires specific discussion